Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The daily Top 10 COVID papers

Ovarian Neoplasms

Free Subscription 07.12.2020 2 Am J Obstet Gynecol 2 Eur J Obstet Gynecol Reprod Biol 3 Gynecol Oncol 1 J Natl Cancer Inst 1 Lancet Oncol 1 Obstet Gynecol 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Obstet Gynecol

1. CHAMBERS LM, Morton M, Lampert E, Yao M, et al
   Use of Prophylactic Closed Incision Negative Pressure Therapy Is Associated with Reduced Surgical Site Infections in Gynecologic Oncology Patients Undergoing Laparotomy.
   Am J Obstet Gynecol. 2020 May 14. pii: S0002-9378(20)30536.
   PubMed         Abstract available
   
   
2. MANDELBAUM RS, Adams CL, Yoshihara K, Nusbaum DJ, et al
   The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecological disease in the United States.
   Am J Obstet Gynecol. 2020 Apr 30. pii: S0002-9378(20)30514.
   PubMed         Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

3. TANG X, Zhang X, Liu X, Zheng T, et al
   A novel laparoscopy-based model for the prediction of optimal cytoreduction and prognosis of epithelial ovarian cancer in a Chinese population.
   Eur J Obstet Gynecol Reprod Biol. 2020;256:256-262.
   PubMed         Abstract available
   
   
4. RUDAITIS V, Mikliusas V, Januska G, Jukna P, et al
   The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
   Eur J Obstet Gynecol Reprod Biol. 2020;247:26-31.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
   Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
   Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
   PubMed         Abstract available
   
   
6. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
   Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
   Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
   PubMed         Abstract available
   
   
7. WU L, Zhu J, Yin R, Wu X, et al
   Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
   Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
   PubMed         Abstract available
   
   

   
   J Natl Cancer Inst

8. PERES LC, Bethea TN, Camacho TF, Bandera EV, et al
   Racial differences in population attributable risk for epithelial ovarian cancer in the OCWAA Consortium.
   J Natl Cancer Inst. 2020 Nov 30. pii: 6012358. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Lancet Oncol

9. ROCCONI RP, Grosen EA, Ghamande SA, Chan JK, et al
   Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
   Lancet Oncol. 2020;21:1661-1672.
   PubMed         Abstract available
   
   

   
   Obstet Gynecol

10. KURNIT KC, Fleming GF, Lengyel E
    Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    Obstet Gynecol. 2020 Dec 3. doi: 10.1097/AOG.0000000000004173.
    PubMed         Abstract available
    
    

    
    PLoS One

11. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

12. KIM O, Park EY, Kwon SY, Shin S, et al
    Targeting progesterone signaling prevents metastatic ovarian cancer.
    Proc Natl Acad Sci U S A. 2020 Dec 1. pii: 2013595117.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: